Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02159859 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients
A Phase 2 study of End Stage Renal Disease, sponsored by Corewell Health East.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT02159859: Completed Phase 2 study of End Stage Renal Disease, sponsored by Corewell Health East.
NCT02159859 is a Phase 2 study of End Stage Renal Disease that has completed, run by Corewell Health East. The registered enrollment target is 7 participants, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02159859, a Phase 2 study of End Stage Renal Disease, has completed, sponsored by Corewell Health East.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.
Primary Outcome
Mean Cmax will be calculated from a series of ertapenem concentration from the blood samples, i.e.once after hemodialysis session prior to ertapenem administration, and at 0.5, 1, 2, 6, 12 hours after the administration of one gram ertapenem over five minutes, and once before the next hemodialysis session
Conditions Studied
Interventions
- DRUG Ertapenem
Study Locations (1)
Michigan
- Oakwood Hospital - Dearborn - Dearborn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 2 |
What the finished NCT02159859 record still lists
NCT02159859 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 833-participant average among 86 other End Stage Renal Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with End Stage Renal Disease appearing as the primary indexed condition, and to 1 intervention - of which Ertapenem is the first listed.
NCT02159859 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02159859 about?
NCT02159859 is a clinical study titled "Pharmacokinetics and Optimal Dose of Ertapenem in Hemodialysis Patients". The purpose of this study is to determine the amount of ertapenem in the blood over time between hemodialysis session.
What is the current status of trial NCT02159859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-12. Estimated completion is 2016-04.
What conditions does trial NCT02159859 study?
This clinical trial studies the following conditions: End Stage Renal Disease.
What interventions are being tested in trial NCT02159859?
The interventions under investigation include: Ertapenem (DRUG).
Who is sponsoring clinical trial NCT02159859?
This trial is sponsored by Corewell Health East, which has 106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02159859 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02159859's enrollment target sits among peer trials
7 84th of 86 higher than 2 of 86 other End Stage Renal Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
RECRUITING · Phase 2
-
Safety and Efficacy of Empagliflozin in Hemodialysis
RECRUITING · Phase 2
-
Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
RECRUITING · Phase 2
-
Communication During Hospitalization About Resuscitation Trial
ACTIVE NOT RECRUITING · Phase 2
-
The Effects of Resistance Exercise and Protein Supplementation in Hemodialysis Patients
COMPLETED · Phase 2
-
Phase II Randomized Study of the Effects of Growth Hormone on Children and Adolescents on Maintenance Dialysis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia